Getting Started With ZEPOSIA
ZEPOSIA is the First and Only S1P With No First-Dose Observation Required
NO First-Dose Observation Required
NO Genetic Testing Required
NO Ophthalmic Testing Required for Most Patients4a
Obtain a recent CBC (within 6 months or after discontinuation of prior MS therapy)
Obtain an ECG to determine whether preexisting conduction abnormalities are present
Obtain transaminase and total bilirubin levels (within 6 months)
Evaluate current and prior medications
Patients without a confirmed history of VZV or without documented VZV vaccination should be tested for antibodies. If VZV or other live attenuated immunizations are required, administer at least 1 month prior to initiation
An Up-Titration Schedule Should Be Used to Reach the Maintenance Dose, as a Transient Decrease in Heart Rate and AV Conduction Delays May Occur1
The Mean (CV%) Plasma Half-Life (t1/2) of ZEPOSIA Was Approximately 21 Hours (15%).1
The Mean Half-Life of the Active Metabolite CC112273 Was Approximately 11 Days.1
Note: The heart rate data shown here for ZEPOSIA include all patients who received ZEPOSIA (SUNBEAM, n=901; RADIANCE, n=873), including those who received ZEPOSIA 0.92 mg and those who received ZEPOSIA 0.46 mg (not approved for maintenance dose). All patients received 0.23 mg on Day 1, regardless of maintenance dose.
Heart Rate Data for Day 1 Initiation Dose (0.23 mg)1,5-7
aDiabetes mellitus and uveitis increase the risk of macular edema; patients with a history of these conditions should have an ophthalmic evaluation of the fundus, including the macula, prior to treatment initiation. A prompt ophthalmic evaluation is recommended if there is any change in vision while taking ZEPOSIA.1
CBC=complete blood count; ECG=electrocardiogram; VZV=varicella-zoster virus.
This information is intended for U.S. Healthcare Professionals.